Viral Vectors And Plasmid DNA Manufacturing Market
- 2026 年市場規模
- USD 1,798.6 Mn
- 2033 年預估規模
- USD 7,571.1 Mn
- 年複合成長率 CAGR
- 23%
以上數字由 Coherent Market Insights 於本報告中提出，量子訊息原樣引用。
授權報價
| Single User Price | $4,500 USD |
| Enterprise License | $10,000 USD |
完整報告名稱與涵蓋範圍
Viral Vectors And Plasmid DNA Manufacturing Market, By Product Type (Viral Vector (Retroviral Vectors, Adenoviral Vectors, Lentiviral Vectors, Adeno-associated Viral Vectors, Others), Plasma DNA, Non-viral DNA Vectors), By Therapeutic Application (Cancer, Inherited Disorders, Vitrectomy Surgery Devices, Infectious Diseases and Others), By End Product (DNA Vaccines, Gene Therapy, Immunotherapy, Others), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)
報告摘要
Viral vectors aids in transferring genetic material into target cells and therefore, used in various therapeutic areas. Viral vectors can be significantly used in vaccines development against pathogens such as Mycobacterium tuberculosis, Plasmodium falciparum, HIV, and various bio-threat targets such as filoviruses. Plasmid DNA (pDNA) is gaining traction for clinical research applications in genetic vaccination and gene therapy. It is becoming increasingly useful as novel biotechnology product for DNA vaccines and gene medicines. It can be directly used as a therapeutic agent and indirectly used for various applications such as a starting material for transient transfection to produce transient proteins and viral vector constructs. Furthermore, pDNA is used as a master-template product to support production of new and developing biopharmaceutical products and processes such as cell therapies.
Market Dynamics
Increasing approvals by regulatory authorities for novel gene therapies is expected to drive growth of the gene therapy segment. For instance, in September 2017, GeneOne Life Science, Inc., received approval from the South Korean Ministry of Food and Drug Safety (KMFDS) for an Investigational New Drug application for a Phase I/IIa study of its investigational vaccine, GLS-5300, against the Middle East Respiratory Syndrome coronavirus (MERSCoV). Moreover, in May 2019, AveXis Inc. received the U.S. Food and Drug Administration approval for its Zolgensma (onasemnogene abeparvovec-xioi), an adeno-associated virus vector-based gene therapy for the treatment of pinal muscular atrophy (SMA) in children less than two years old.
Key features of the study
• This report provides in-depth analysis of the global viral vector and plasmid DNA manufacturing market and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2019–2027), considering 2018 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global viral vector and plasmid DNA manufacturing market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
• Key companies covered as a part of this study include Lonza Group AG, FinVector Vision Therapies, Cobra Biologics and Pharmaceutical Services, Sigma-Aldrich Co. LLC, VGXI, Inc., VIROVEK, SIRION Biotech GmbH, FUJIFILM Diosynth Biotechnologies U.S.A., Inc., Sanofi, Cell and Gene Therapy Catapult, Brammer Bio, and MassBiologics.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
• The global viral vector and plasmid DNA manufacturing market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global viral vector and plasmid DNA manufacturing market
Market Segmentation
• By Product Type
o Viral Vector
Retroviral Vectors
Adenoviral Vectors
Lentiviral Vectors
Adeno-associated Viral Vectors
Others
o Plasma DNA
o Non-viral DNA Vectors
• By Therapeutic Application
o Cancer
o Inherited Disorders
o Vitrectomy Surgery Devices
o Infectious Diseases
o Others
• By End Product
o DNA Vaccines
o Gene Therapy
o Immunotherapy
o Others
• By Region
o North America
U.S.
Canada
o Latin America
Brazil
Mexico
Argentina
Rest of Latin America
o Europe
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
o Asia Pacific
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
o Middle East
GCC
Israel
Rest of Middle East
o Africa
South Africa
Central Africa
North Africa
• Key Players
o Lonza Group AG
o FinVector Vision Therapies
o Cobra Biologics and Pharmaceutical Services
o Sigma-Aldrich Co. LLC
o VGXI, Inc.
o VIROVEK
o SIRION Biotech GmbH
o FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
o Sanofi
o Cell and Gene Therapy Catapult
o Brammer Bio
o MassBiologics
目錄 Table of Contents
Table of Contents
1. Research Objectives and Assumptions
o Research Objectives
o Assumptions
o Abbreviations
2. Market Purview
o Report Description
Market Definition and Scope
o Executive Summary
Market Snippet, By Product Type
Market Snippet, By Therapeutic Application
Market Snippet, By End Product
Market Snippet, By Region
o Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
o Market Dynamics
Drivers
Restraints
Market Opportunities
o Impact Analysis of DROs
o Comparative Analysis of Different Types of Viral Systems
o Collaborations, Partnerships, And Agreements
o Pipeline Analysis
o New Product Launches
o Investment Opportunities
o Regulatory Scenario
o Strategies For Product Development and Application Pathways
o Brand Analysis
o Cell & Gene Therapy Manufacturing Capacities Globally
o Porter’s Analysis
4. Global Viral Vector and Plasmid DNA Manufacturing Market, By Product Type, 2021 – 2033, (USD Mn)
o Introduction
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2021 – 2033
Segment Trends
o Viral Vector
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021 – 2033, (USD Mn)
o Retroviral Vectors
o Adenoviral Vectors
o Lentiviral Vectors
o Adeno-associated Viral Vectors
o Others
o Plasma DNA
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021 – 2033, (USD Mn)
o Non-Viral DNA Vectors
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021 – 2033, (USD Mn)
5. Global Viral Vector and Plasmid DNA Manufacturing Market, By Therapeutic Application, 2021 – 2033, (USD Mn)
o Introduction
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2021 – 2033
Segment Trends
o Cancer
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021 – 2033, (USD Mn)
o Inherited Disorders
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021 – 2033, (USD Mn)
o Infectious Diseases
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021 – 2033, (USD Mn)
o Others
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021 – 2033, (USD Mn)
6. Global Viral Vector and Plasmid DNA Manufacturing Market, By End Product, 2021 – 2033, (USD Mn)
o Introduction
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2021 – 2033
Segment Trends
o DNA Vaccines
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021 – 2033, (USD Mn)
o Gene Therapy
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021 – 2033, (USD Mn)
o Immunotherapy
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021 – 2033, (USD Mn)
o Others
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021 – 2033, (USD Mn)
7. Global Viral Vector and Plasmid DNA Manufacturing Market, By Region, 2021 – 2033, (USD Mn)
o Introduction
Market Share Analysis, By Region, 2026 and 2033 (%)
Y-o-Y Growth Analysis, For Regions, 2017–2027
o North America
Market Size and Forecast, By Product Type, 2021 – 2033, (USD Mn)
Market Size and Forecast, By Therapeutic Application, 2021 – 2033, (USD Mn)
Market Size and Forecast, By End Product, 2021 – 2033, (USD Mn)
Market Size and Forecast, By Country, 2021 – 2033, (USD Mn)
o U.S.
o Canada
o Latin America
Market Size and Forecast, By Product Type, 2021 – 2033, (USD Mn)
Market Size and Forecast, By Therapeutic Application, 2021 – 2033, (USD Mn)
Market Size and Forecast, By End Product, 2021 – 2033, (USD Mn)
Market Size and Forecast, By Country, 2021 – 2033, (USD Mn)
o Brazil
o Mexico
o Argentina
o Rest of Latin America
o Europe
Market Size and Forecast, By Product Type, 2021 – 2033, (USD Mn)
Market Size and Forecast, By Therapeutic Application, 2021 – 2033, (USD Mn)
Market Size and Forecast, By End Product, 2021 – 2033, (USD Mn)
Market Size and Forecast, By Country, 2021 – 2033, (USD Mn)
o Germany
o U.K.
o France
o Italy
o Spain
o Russia
o Rest of Europe
o Asia Pacific
Market Size and Forecast, By Product Type, 2021 – 2033, (USD Mn)
Market Size and Forecast, By Therapeutic Application, 2021 – 2033, (USD Mn)
Market Size and Forecast, By End Product, 2021 – 2033, (USD Mn)
Market Size and Forecast, By Country, 2021 – 2033, (USD Mn)
o China
o India
o Japan
o Australia
o South Korea
o ASEAN
o Rest of Asia Pacific
o Middle East
Market Size and Forecast, By Product Type, 2021 – 2033, (USD Mn)
Market Size and Forecast, By Therapeutic Application, 2021 – 2033, (USD Mn)
Market Size and Forecast, By End Product, 2021 – 2033, (USD Mn)
Market Size and Forecast, By Country, 2021 – 2033, (USD Mn)
o GCC
o Israel
o Rest of Middle East
o Africa
Market Size and Forecast, By Product Type, 2021 – 2033, (USD Mn)
Market Size and Forecast, By Therapeutic Application, 2021 – 2033, (USD Mn)
Market Size and Forecast, By End Product, 2021 – 2033, (USD Mn)
Market Size and Forecast, By Country/Region, 2021 – 2033, (USD Mn)
o South Africa
o Central Africa
o North Africa
8. Competitive Landscape
o Heat Map Analysis
o Market Share Analysis
Lonza Group AG
o Company Overview
o Product Portfolio
o Financial Overview
o Key Highlights
o Market Strategies
FinVector Vision Therapies
o Company Overview
o Product Portfolio
o Financial Overview
o Key Highlights
o Market Strategies
Cobra Biologics and Pharmaceutical Services
o Company Overview
o Product Portfolio
o Financial Overview
o Key Highlights
o Market Strategies
Sigma-Aldrich Co. LLC
o Company Overview
o Product Portfolio
o Financial Overview
o Key Highlights
o Market Strategies
VGXI, Inc.
o Company Overview
o Product Portfolio
o Financial Overview
o Key Highlights
o Market Strategies
VIROVEK
o Company Overview
o Product Portfolio
o Financial Overview
o Key Highlights
o Market Strategies
SIRION Biotech GmbH
o Company Overview
o Product Portfolio
o Financial Overview
o Key Highlights
o Market Strategies
FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
o Company Overview
o Product Portfolio
o Financial Overview
o Key Highlights
o Market Strategies
Sanofi
o Company Overview
o Product Portfolio
o Financial Overview
o Key Highlights
o Market Strategies
Cell and Gene Therapy Catapult
o Company Overview
o Product Portfolio
o Financial Overview
o Key Highlights
o Market Strategies
Brammer Bio
o Company Overview
o Product Portfolio
o Financial Overview
o Key Highlights
o Market Strategies
MassBiologics
o Company Overview
o Product Portfolio
o Financial Overview
o Key Highlights
o Market Strategies
o Analyst Views
9. Section
o References
o Research Methodology
o About Us and Sales Contact
Browse 34 market data tables and 33 figures on Viral Vector and Plasmid DNA Manufacturing Market” - Global forecast to 2033.
提及公司
同分類最新報告（醫療與生命科學）
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 Coherent Market Insights 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們